Physician profile
Michael Pope
NPI 1457353997
$983.83
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $106 · 2021: $364 · 2022: $153.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $242.87 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $224.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $94.93 | 2019-2021 | |
| Corium, LLC | $86.18 | 2021-2022 | |
| Shire North American Group INC | $70.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.44 | 2020-2021 | |
| Sobi, INC | $50.21 | 2021-2022 | |
| Neos Therapeutics, Lp | $47.24 | 2019-2020 | |
| Genentech USA, INC. | $27.05 | 2019-2020 | |
| Cranial Technologies, INC | $26.62 | 2019-2020 | |
| Pfizer INC. | $24.03 | 2021 | |
| Tris Pharma INC | $21.49 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $12.42 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.